(KALV) KalVista Pharmaceuticals, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(KALV) KalVista Pharmaceuticals, Inc. Complete Analysis Pack
Visual. Strategic. Downloadable.
This KalVista Pharmaceuticals, Inc. BCG Matrix is a simple strategic tool for evaluating the company’s portfolio across Stars, Cash Cows, Question Marks, and Dogs, helping with investment, research, and planning decisions. The page already shows a real preview of the analysis, so you can see the actual format and content before you buy. Purchase the full version to get the complete ready-to-use report.
Stars
EKTERLY (sebetralstat) — 2025 FDA approval
EKTERLY (sebetralstat) won FDA approval in 2025, giving KalVista Pharmaceuticals, Inc. its first approved product. It is an oral, on-demand treatment for hereditary angioedema attacks, a rare disease affecting about 1 in 50,000 people. That makes EKTERLY the clearest Star in KalVista’s portfolio, with the strongest launch and growth potential.
EKTERLY — oral on-demand HAE
EKTERLY targets acute hereditary angioedema attacks, a rare disease affecting about 1 in 50,000 people worldwide. Oral on-demand dosing is a clear edge over injectables and infusions, so it can win share fast if access and reimbursement widen. That makes it a Star with strong growth potential.
EKTERLY — Phase 3 KONFIDENT
EKTERLY’s Phase 3 KONFIDENT trial delivered the pivotal data behind KalVista Pharmaceuticals, Inc.’s July 2025 FDA approval, making it the first oral on-demand HAE treatment. That late-stage win cuts clinical risk versus the rest of the pipeline and gives KalVista Pharmaceuticals, Inc. a real launch base at year-end 2025. In HAE, a confirmed approved asset matters: KONFIDENT is now the company’s main value driver.
EKTERLY — first-in-class oral kallikrein inhibitor
EKTERLY (sebetralstat) is KalVista Pharmaceuticals, Inc.'s first-in-class oral plasma kallikrein inhibitor, and its 2025 FDA approval gives KalVista first-mover edge in hereditary angioedema, a disease affecting about 1 in 50,000 people. That early status can lift physician awareness and repeat use fast.
If uptake stays strong, EKTERLY can move from a Star to cash-cow economics as launch costs fade and scripts scale.
- First oral kallikrein inhibitor
- 2025 FDA approval
- Builds brand and physician habit
EKTERLY — U.S. launch 2025
EKTERLY’s U.S. launch in 2025 marks KalVista Pharmaceuticals, Inc. moving from development to sales execution. The FDA approved EKTERLY on June 16, 2025 for hereditary angioedema attacks, so launch spending should rise first, then revenue can scale as prescriptions build through year-end 2025.
- Launch phase raises SG&A.
- Approval date: June 16, 2025.
- Revenue growth depends on script uptake.
- EKTERLY becomes the main growth engine.
EKTERLY Could Power KalVista’s 2025 Growth
EKTERLY (sebetralstat) is KalVista Pharmaceuticals, Inc.’s Star asset: FDA approved on June 16, 2025, it became the first oral on-demand treatment for hereditary angioedema attacks. HAE affects about 1 in 50,000 people, so the addressable market is small but high value. Strong uptake and access could make it KalVista Pharmaceuticals, Inc.’s main 2025 growth engine.
| Star asset | Key 2025 data |
|---|---|
| EKTERLY | FDA approval: June 16, 2025 |
| Indication | On-demand HAE attacks |
| Market | About 1 in 50,000 people |
What is included in the product
Detailed Word Document
KalVista’s BCG Matrix spots pipeline assets to invest, hold, or divest amid biotech competition and market uncertainty.
Editable Excel File
Clean KalVista Pharmaceuticals BCG Matrix that spotlights quadrants fast and removes presentation clutter
Reference Sources
Provides a credible source trail for KalVista Pharmaceuticals, Inc. that helps verify claims fast and supports better decisions.
Cash Cows
0 mature branded products
At year-end 2025, KalVista Pharmaceuticals, Inc. had 0 mature branded products, so there was no legacy franchise generating steady, low-growth cash. The business was still centered on its first launch and an R&D pipeline, with FY2025 results still in an investment phase. So, in BCG terms, there was no cash cow to milk.
0 legacy revenue streams
KalVista Pharmaceuticals, Inc. had 0 legacy revenue streams in FY2025: no older marketed brand was generating stable, recurring cash. The business was still shifting from clinical stage to commercial stage, so cash creation stayed early and concentrated in EKTERLY, its only commercial product. That means the Cash Cows box was not yet filled by a mature portfolio.
0 mature market leaders
KalVista Pharmaceuticals, Inc. had 0 cash cows because cash cows need high share in a mature market, and by FY2025 it had not built that kind of durable leadership. EKTERLY won FDA approval in June 2025, but KalVista was still in early HAE commercialization and share building, not harvesting. With no broad, recurring revenue base yet, the BCG box stays at 0 mature market leaders.
0 low-growth franchises
KalVista Pharmaceuticals, Inc. had no clear cash cow in FY2025: it did not show a low-growth, high-share franchise that could reliably fund the rest of the business. With product revenue still at $0, the company stayed dependent on launch execution and pipeline progress rather than mature product cash flow.
- FY2025: no cash-cow franchise
- Product revenue: $0
- Growth story still launch-led
- Future value depends on pipeline
R&D funded by capital
KalVista Pharmaceuticals, Inc. still looks like a capital-funded biotech, not a true cash cow: it reported $148.8 million in cash, cash equivalents and marketable securities at October 31, 2024, while FY2024 R&D was $103.7 million. That means the company was funding development and launch work with outside capital, not harvesting excess product cash.
- Cash funded R&D, not surplus cash flow
- FY2024 R&D: $103.7 million
- Cash and securities: $148.8 million
- Early commercial biotech profile
KalVista Still Has No Cash Cows—Just an Early-Stage Launch Story
KalVista Pharmaceuticals, Inc. had no Cash Cows in FY2025. EKTERLY was its only product launch, but at year-end 2025 the company still had no mature, low-growth franchise generating steady cash, and product revenue remained $0. It was still a launch-and-R&D biotech, not a harvest phase business.
| Metric | FY2025 |
|---|---|
| Cash cows | 0 |
| Product revenue | $0 |
| Commercial status | Early launch |
| Model | R&D funded |
Full Version Awaits
KalVista Pharmaceuticals, Inc. Reference Sources
You’re previewing the exact KalVista Pharmaceuticals, Inc. BCG Matrix report you’ll receive after purchase. No demo pages or placeholder content—just the complete, fully formatted file. Once purchased, the same document is instantly available for download and use. It’s ready for analysis, presentation, or strategic planning right away.
Dogs
KVD001 — Phase II DME
KVD001 finished a Phase II trial in diabetic macular edema, but KalVista Pharmaceuticals, Inc. has not turned it into a marketed drug. In BCG terms, that means low share and weak commercial upside, with no sales base to build from. With no approved product revenue, KVD001 sits as a Dogs asset unless new data or partnering changes its path.
DME — no commercialization
DME remained a Dog for KalVista Pharmaceuticals, Inc. through FY2025: it had no approved brand and no commercialization, so revenue contribution was 0. That places the program in a low-share, low-growth bucket, with no visible market pull by year-end 2025. In BCG terms, it is a capital sink unless the asset gains a clear regulatory path.
Legacy plasma kallikrein asset
KVD001 is part of KalVista Pharmaceuticals, Inc. earlier plasma kallikrein work, and it now sits outside the company’s growth engine. With KalVista’s focus having shifted to newer kallikrein assets, capital tied to KVD001 is unlikely to deliver meaningful return. In BCG Matrix terms, it fits the Dogs bucket: low strategic value and weak future cash potential.
No disclosed late-stage path
KalVista Pharmaceuticals, Inc. ended FY2025 focused on HAE launch, not a DME comeback, and it disclosed no clear late-stage path for KVD001. That makes KVD001 a weak Dogs asset in the BCG Matrix: low strategic visibility, no near-term catalyst, and limited capital priority versus the launch program.
- No late-stage KVD001 path disclosed
- FY2025 focus stayed on HAE launch
- Weak strategic value for capital allocation
Non-core ophthalmology program
At year-end 2025, KalVista Pharmaceuticals, Inc. had shifted its commercial focus to hereditary angioedema, so the ophthalmology program sat outside the main growth story. In BCG terms, that makes the DME asset a Dog: low strategic priority, limited near-term cash return, and a likely drag on capital and management time.
- HAE was the core focus in 2025
- Ophthalmology was peripheral
- DME looked Dog-like
KalVista’s DME Asset Remains a Low-Priority “Dog” in FY2025
KalVista Pharmaceuticals, Inc.’s DME asset stayed a Dog in FY2025: no approved product, no sales, and no disclosed late-stage path. With HAE as the capital focus, KVD001 had near-zero strategic pull and limited cash potential. That leaves it a low-share, low-growth program that is hard to justify versus launch spending.
| Item | FY2025 | BCG view |
|---|---|---|
| KVD001/DME | 0 revenue | Dog |
| Approval status | No approval | Weak share |
| Company focus | HAE launch | Low priority |
Question Marks
KVD824 — oral HAE candidate
KVD824 is KalVista Pharmaceuticals, Inc.'s oral HAE candidate in a rare-disease market that affects about 1 in 50,000 people worldwide. By end-2025, it had no commercial share, so it fits the BCG Question Mark slot: low share today, but with upside if it can win in a market where oral prophylaxis is a key unmet need.
Factor XIIa program — preclinical
KalVista Pharmaceuticals, Inc.'s Factor XIIa oral inhibitor program is still preclinical, so it has no market share or sales yet. Preclinical programs can still matter, but they usually burn R&D cash before any proof in patients; KalVista reported $108.1 million in research and development expense in fiscal 2025. That makes this a classic Question Mark in the BCG Matrix: high upside, but still unproven.
Next oral small-molecule HAE assets
KalVista Pharmaceuticals, Inc. is still building beyond EKTERLY, with next oral small-molecule HAE assets centered on oral protease inhibition. HAE remains a small but growing niche, with about 1 in 50,000 people affected, so the addressable pool is real. But these programs are still early, and market share is not yet proven, so they fit Question Marks.
Pipeline expansion beyond EKTERLY
Pipeline expansion beyond EKTERLY is a Question Mark because KalVista Pharmaceuticals, Inc. had one approved drug, EKTERLY, while follow-on programs were still in development at year-end 2025. Their value depends on proving they can repeat EKTERLY’s launch and commercial traction. Until that happens, they stay high-potential but uncertain.
- 1 approved product: EKTERLY
- Follow-on programs: still in development
- Outcome: high upside, high risk
Low-share launch-stage science
KalVista Pharmaceuticals, Inc. fits the Question Marks bucket because its earlier-stage HAE programs have development upside but no meaningful sales base yet. That means cash must be put into trials, regulatory work, and pipeline proof before any Star-like payoff can emerge. The upside is real, but so is the risk: if data or approval misses, value can drop fast.
- High potential, low current share
- Needs funding before scale-up
- Binary trial and approval risk
KalVista’s Pipeline: High Upside, No Sales Yet
KalVista Pharmaceuticals, Inc.'s Question Marks are its early HAE pipeline assets: they have upside, but no sales yet. In fiscal 2025, research and development expense was $108.1 million, showing the cash burn needed before these programs can prove demand.
With only EKTERLY approved at year-end 2025, follow-on assets still had low share and high execution risk. That makes them classic BCG Question Marks: small current weight, but possible future growth.
| Item | FY2025 |
|---|---|
| R&D expense | $108.1 million |
| Approved products | 1 |
| Question Mark status | High upside, no sales |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.